Designed for Scalable, Reproducible Cell Culture From Research to Clinical Manufacturing
 |
Human Platelet Lysate (hPL) is a human-derived, xeno-free alternative to fetal bovine serum (FBS), developed to address the scientific, ethical, and translational limitations of animal-derived supplements. With a physiologically relevant growth factor profile and high batch consistency, hPL enables robust and reproducible expansion of human cells while supporting modern regulatory and translational expectations. Key benefits:
Compatible with MSCs, T cells, NK cells, iPSCs, fibroblasts, and widely used cell lines. |
|
Lysantum Premium & Lysantum Ultra
| Category | Lysantum Premium (Research & Clinical) | Lysantum Ultra (Research & Clinical) |
|---|---|---|
| HPL Type | Premium hPL generated from platelet concentrate (transfusion grade). Both Lysantum Premium & Lysantum Ultra have been successfully applied across multiple advanced cell types. | Next generation platelet lysate that contains an even higher concentration of growth factors, resulting in a different composition. Both Lysantum Premium & Lysantum Ultra have been successfully applied across multiple advanced cell types. |
| Media compatibility | Low-Ca²⁺ media such as DMEM/F-12, IMDM, Ham’s F-12, RPMI-1640, etc. | Broad media compatibility including DMEM, DMEM/F-12, αMEM, IMDM, Ham’s F-12. |
| Intended use |
Research Grade: For optimal cost-effectiveness, Research grade hPL is the best choice.
The products have the same composition as their clinical counterparts and are therefore equally efficient.
Applications include R&D, method development, and translational research.
Clinical Grade: Produced with more extensive testing, documentation, and traceability. Suitable for early clinical workflows, clinical manufacturing, and ATMP production. |
|
| Formats | 100 mL, 500 mL | 180 mL |
| Visual reference |
|
|
| Category | Lysantum Premium (Research & Clinical) | Lysantum Ultra (Research & Clinical) | ||||
| Media Compatibility | Low-Ca²⁺ media such as DMEM/F-12, IMDM, Ham’s F-12, RPMI-1640, etc. | Broad media compatibility including DMEM, DMEM/F-12, αMEM, IMDM, Ham’s F-12 | ||||
| Intended Use |
|
|
||||
| Formats | 100 ml, 500 mL | 180 mL | ||||
| Visual Reference |  |
 |
||||
hPL vs FBS
Superior Cell Expansion
- ≈2× faster proliferation with hPL versus FBS
- Requires fewer supplements
High Batch-to-Batch Consistency
- Provides superior batch-to-batch consistency compared to FBS, enabling predictable performance for advanced in vitro models and scalable bioprocesses
- Wiley Online Library
hPL Has Been Successfully Applied Across Multiple Advanced Cell Types
Manufacturing Quality & Regulatory Alignment
Quality & Safety
- NAT testing for HIV, HBV, and HCV
- Pathogen inactivation
- Closed system
- Full donor & batch traceability
- Non remunerated EU donors
Regulatory & Ethical Fit
- Aligned with modern translational and regulatory expectations
- Supports 3Rs/NAMs and human-relevant model systems
GMP-Aligned Production
- Compliant with applicable standards:
- ISO 13485 & ISO 20399
- European Pharmacopoeia
- Closed-system manufacturing workflow
- Scalable batch up to 200 L
-
References
Figure 1: Radajewska A, Przybyszewski O, Emhemmed F, Muller CD, Barg E, Moreira H. “Three-dimensional in vitro culture systems in anticancer drug discovery targeted on cancer stem cells." Am J Cancer Res. 2021 Oct 15;11(10):4931-4946. PMID: 34765301; PMCID: PMC8569359.
Figure 2: Courtesy of Apricell Biotechnology Inc..
Figure 3 : Courtesy of Kugelmeiers.
Figure 4: Courtesy of 4Dcell.
Integrate A Human-Relevant, Xeno-Free Supplement Into Your Manufacturing Or Therapeutic Workflow
Whether you are developing advanced in vitro models, scaling cell therapy processes, or transitioning away from FBS, Lysantum Premium & Lysantum Ultra provide a high-performance, reproducible and clinically aligned solution.